D. Donnelly‐Roberts

发表

D. Donnelly-roberts, C. Shieh, P. Honore, 2008, Journal of Pharmacology and Experimental Therapeutics.

Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors.

D. Donnelly-roberts, R. Porsolt, S. Arneric, 1998, Science.

Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor.

D. Donnelly-roberts, S. Arneric, J. Sullivan, 1996, The Journal of pharmacology and experimental therapeutics.

Central Mechanisms Regulating Penile Erection in Conscious Rats: The Dopaminergic Systems Related to the Proerectile Effect of Apomorphine

D. Donnelly-roberts, J. Sullivan, J. Brioni, 2004, Journal of Pharmacology and Experimental Therapeutics.

eIF2B activator prevents neurological defects caused by a chronic integrated stress response

Nimrod D. Rubinstein, D. Donnelly-roberts, A. Swensen, 2018, bioRxiv.

Therapeutic Potential of α7 Nicotinic Acetylcholine Receptors

D. Bertrand, D. Donnelly-roberts, Chih-Hung Lee, 2015, Pharmacological Reviews.

Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors.

D. Donnelly-roberts, S. Arneric, C. Briggs, 1998, Journal of medicinal chemistry.

Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors.

D. Donnelly-roberts, Y. Martin, S. Arneric, 1996, Journal of medicinal chemistry.

(+/-)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors.

D. Donnelly-roberts, J. Sullivan, D. Anderson, 1994, The Journal of pharmacology and experimental therapeutics.

(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization.

D. Donnelly-roberts, S. Arneric, J. Sullivan, 1994, The Journal of pharmacology and experimental therapeutics.

The antihyperalgesic activity of a selective P2X7 receptor antagonist, A-839977, is lost in IL-1αβ knockout mice

D. Donnelly-roberts, Y. Iwakura, P. Chandran, 2009, Behavioural Brain Research.

Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors

D. Donnelly-roberts, M. Jarvis, P. Han, 2009, British journal of pharmacology.

[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors

D. Donnelly-roberts, M. Jarvis, Ying Wang, 2009, Neuropharmacology.

D. Donnelly-roberts, C. Shieh, P. Honore, 2007, Neuroscience.

A-740003 [N-(1-{[(Cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a Novel and Selective P2X7 Receptor Antagonist, Dose-Dependently Reduces Neuropathic Pain in the Rat

D. Donnelly-roberts, J. Sullivan, P. Chandran, 2006, Journal of Pharmacology and Experimental Therapeutics.

Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists.

D. Donnelly-roberts, P. Honore, M. Jarvis, 2006, Journal of medicinal chemistry.

Cloning and sequence of the human α7 nicotinic acetylcholine receptor

D. Donnelly-roberts, T. Giordano, L. Monteggia, 1993 .

A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: In Vitro pharmacological properties of a novel, high affinity α4β2 nicotinic acetylcholine receptor ligand

D. Donnelly-roberts, D. Mckenna, S. Arneric, 1996, Neuropharmacology.

Selective P2X7 receptor antagonists for chronic inflammation and pain

D. Donnelly-roberts, M. Jarvis, W. Carroll, 2008, Purinergic Signalling.

Structure-activity relationship studies on N'-aryl carbohydrazide P2X7 antagonists.

D. Donnelly-roberts, P. Honore, M. Jarvis, 2008, Journal of medicinal chemistry.

Novel and potent 3-(2,3-dichlorophenyl)-4-(benzyl)-4H-1,2,4-triazole P2X7 antagonists.

D. Donnelly-roberts, P. Honore, M. Jarvis, 2007, Bioorganic & medicinal chemistry letters.

Reduced nicotinic receptor-mediated antinociception following in vivo antisense knock-down in rat

D. Donnelly-roberts, M. Decker, R. Bitner, 2000, Brain Research.

Mitogen-Activated Protein Kinase and Caspase Signaling Pathways Are Required for P2X7 Receptor (P2X7R)-Induced Pore Formation in Human THP-1 Cells

D. Donnelly-roberts, M. Jarvis, C. Faltynek, 2004, Journal of Pharmacology and Experimental Therapeutics.

A-85380: a pharmacological probe for the preclinical and clinical investigation of the alphabeta neuronal nicotinic acetylcholine receptor.

D. Donnelly-roberts, C. Briggs, L. Rueter, 2006, CNS drug reviews.

The role of neuronal nicotinic acetylcholine receptors in antinociception: Effects of ABT-594

D. Donnelly-roberts, S. Arneric, C. Briggs, 1998, Journal of Physiology-Paris.

Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties.

A. D. Rodrigues, D. Donnelly-roberts, S. Arneric, 1997, Journal of medicinal chemistry.

High Throughput Functional Assays for P2X Receptors

D. Donnelly-roberts, M. Jarvis, M. Namovic, 2012, Current protocols in pharmacology.

Discovery of P2X7 receptor‐selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states

D. Donnelly-roberts, M. Jarvis, D. Donnelly‐Roberts, 2007, British journal of pharmacology.

Erysodine, a competitive antagonist at neuronal nicotinic acetylcholine receptors.

D. Donnelly-roberts, J. Sullivan, D. Anderson, 1995, European journal of pharmacology.

In vitro and in vivo effects of an alpha3 neuronal nicotinic acetylcholine receptor antisense oligonucleotide.

D. Donnelly-roberts, M. Decker, P. Kroeger, 2004, Brain research. Molecular brain research.

GDF15 is a dynamic biomarker of the Integrated Stress Response in the central nervous system

R. Schiffmann, A. Swensen, S. Sanyal, 2023, bioRxiv.

Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats.

D. Donnelly-roberts, J. Sullivan, M. Nakane, 2004, Proceedings of the National Academy of Sciences of the United States of America.

NRF2 activator A-1396076 ameliorates inflammation in autoimmune disease models by inhibiting antigen dependent T cell activation

Christian Goess, P. Richardson, D. Donnelly-roberts, 2020, Journal of translational autoimmunity.

ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders.

D. Donnelly-roberts, G. Gintant, J. Sullivan, 2006, CNS drug reviews.

A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand.

D. Mckenna, S. Arneric, J. Sullivan, 1996, Neuropharmacology.

Functional modulation of human "ganglionic-like" neuronal nicotinic acetylcholine receptors (nAChRs) by L-type calcium channel antagonists.

S. Arneric, J. Sullivan, D. Donnelly‐Roberts, 1995, Biochemical and biophysical research communications.

Functional Characterization of the Novel Neuronal Nicotinic Acetylcholine Receptor Ligand GTS-21 In Vitro and In Vivo

W. J. Jackson, D. Donnelly-roberts, S. Arneric, 1997, Pharmacology Biochemistry and Behavior.

Characterization of psoriasiform dermatitis induced by systemic injection of interleukin‐23 minicircles in mice

D. Donnelly-roberts, P. Honore, R. Edelmayer, 2019, The Journal of dermatology.

Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent: effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice.

D. Donnelly-roberts, S. Arneric, J. Sullivan, 1998, Bioorganic & medicinal chemistry letters.

Reducing inflammation and rescuing FTD-related behavioral deficits in progranulin-deficient mice with α7 nicotinic acetylcholine receptor agonists.

D. Donnelly-roberts, L. Gan, Jinhe Li, 2015, Biochemical pharmacology.

Small Molecule Phenotypic Screen Identifies Novel Regulators of LDLR Expression.

D. Holtzman, D. Donnelly-roberts, E. Mohler, 2020, ACS Chemical Biology.

In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418

D. Donnelly-roberts, S. Arneric, J. Sullivan, 1996, Brain Research.

Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties.

D. Donnelly-roberts, S. Arneric, J. Sullivan, 1995, Alzheimer disease and associated disorders.

Synthesis and SAR of 4-aminocyclopentapyrrolidines as N-type Ca²⁺ channel blockers with analgesic activity.

Jill M. Wetter, R. Henry, A. Swensen, 2012, Bioorganic & medicinal chemistry.

Short-term oral gavage administration of adenine induces a model of fibrotic kidney disease in rats.

D. Donnelly-roberts, M. Gopalakrishnan, S. McGaraughty, 2018, Journal of pharmacological and toxicological methods.

Longitudinal Changes in Measured Glomerular Filtration Rate, Renal Fibrosis and Biomarkers in a Rat Model of Type 2 Diabetic Nephropathy

D. Donnelly-roberts, S. McGaraughty, T. Esbenshade, 2016, American Journal of Nephrology.

Therapeutic Potential of α7 Nicotinic Acetylcholine Receptors

D. Bertrand, Chih-Hung Lee, D. Flood, 2015, Pharmacological Reviews.

Pharmacological characterization of P2X7 receptors in rat peritoneal cells

D. Donnelly-roberts, G. Gintant, M. Jarvis, 2005, Inflammation Research.

Perspectives in Pharmacology Painful Purinergic Receptors

C. Shieh, P. Honore, M. Jarvis, 2008 .

JPET # 105890 PIP 1 Painful Purinergic Receptors

D. Donnelly-roberts, C. Shieh, P. Honore, 2007 .

Small Molecule and Pooled CRISPR Screens Investigating IL17 Signaling Identify BRD2 as a Novel Contributor to Keratinocyte Inflammatory Responses.

D. Donnelly-roberts, Charles Lu, Namjin Chung, 2019, ACS chemical biology.

Sodium dodecyl sulfate- and carbamylcholine-induced changes in circular dichroism spectra of acetylcholine receptor synthetic peptides.

D. Donnelly-roberts, T. Lentz, D. Donnelly‐Roberts, 1993, Brain research. Molecular brain research.

Substitution of Torpedo acetylcholine receptor alpha 1-subunit residues with snake alpha 1- and rat nerve alpha 3-subunit residues in recombinant fusion proteins: effect on alpha-bungarotoxin binding.

D. Donnelly-roberts, T. Lentz, V. Chaturvedi, 1992, Biochemistry.

Evidence for Nicotinic Receptors Potentially Modulating Nociceptive Transmission at the Level of the Primary Sensory Neuron: Studies with F11 Cells

D. Donnelly-roberts, S. Arneric, P. Puttfarcken, 1997, Journal of neurochemistry.

Synthesis and structure-activity relationships of pyridine-modified analogs of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, A-84543, a potent nicotinic acetylcholine receptor agonist.

D. Donnelly-roberts, S. Arneric, J. Sullivan, 1998, Bioorganic & medicinal chemistry letters.

ABT-418: A Novel Cholinergic Channel Activator (ChCA) for the Potential Treatment of Alzheimer’s Disease

A. D. Rodrigues, S. Arneric, J. Sullivan, 1994 .

ABT — 418, a Novel Nicotinic Agonist

A. D. Rodrigues, W. J. Jackson, Y. Martin, 1994 .

Rapid assessment of ligand actions with nicotinic acetylcholine receptors using calcium dynamics and FLIPR

D. Donnelly-roberts, S. Arneric, T. Kuntzweiler, 1998 .

ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization.

D. Donnelly-roberts, D. Mckenna, S. Arneric, 1998, The Journal of pharmacology and experimental therapeutics.

ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties.

D. Donnelly-roberts, D. Mckenna, S. Arneric, 1997, The Journal of pharmacology and experimental therapeutics.

Stable expression and pharmacological properties of the human alpha 7 nicotinic acetylcholine receptor.

D. Bertrand, D. Donnelly-roberts, S. Arneric, 1995, European journal of pharmacology.

Effects of mutations of Torpedo acetylcholine receptor alpha 1 subunit residues 184-200 on alpha-bungarotoxin binding in a recombinant fusion protein.

D. Donnelly-roberts, T. Lentz, V. Chaturvedi, 1993, Biochemistry.

Binding sites for alpha-bungarotoxin and the noncompetitive inhibitor phencyclidine on a synthetic peptide comprising residues 172-227 of the alpha-subunit of the nicotinic acetylcholine receptor.

D. Donnelly-roberts, T. Lentz, D. Donnelly‐Roberts, 1991, Biochemistry.

Preclinical Pharmacology of ABT‐418: A Prototypical Cholinergic Channel Activator for the Potential Treatment of Alzheimer's Disease

A. D. Rodrigues, D. Donnelly-roberts, S. Arneric, 1995 .

Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction.

D. Donnelly-roberts, J. Sullivan, M. Nakane, 2004, Journal of medicinal chemistry.

Synthesis and activity of N-cyanoguanidine-piperazine P2X7 antagonists.

E. Tarcsa, M. Namovic, Kevin R. Woller, 2008, Bioorganic & medicinal chemistry letters.

Synthesis and in vitro activity of N'-cyano-4-(2-phenylacetyl)-N-o-tolylpiperazine-1-carboximidamide P2X7 antagonists.

M. Jarvis, Haipeng Chen, M. Namovic, 2008, Bioorganic & medicinal chemistry letters.

Synthesis and in vitro activity of 1-(2,3-dichlorophenyl)-N-(pyridin-3-ylmethyl)-1H-1,2,4-triazol-5-amine and 4-(2,3-dichlorophenyl)-N-(pyridin-3-ylmethyl)-4H-1,2,4-triazol-3-amine P2X7 antagonists.

D. Donnelly-roberts, M. Jarvis, A. Florjancic, 2008, Bioorganic & medicinal chemistry letters.

Mitogen-Activated Protein Kinase and Caspase Signaling Pathways Are Required for P 2 X 7 Receptor ( P 2 X 7 R )-Induced Pore Formation in Human THP-1 Cells

D. Donnelly-roberts, M. Jarvis, C. Faltynek, 2004 .

Synthesis and in vitro activity of N-benzyl-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine P2X(7) antagonists.

D. Donnelly-roberts, M. Jarvis, C. Faltynek, 2011, Bioorganic & medicinal chemistry letters.

Discovery and biological evaluation of novel cyanoguanidine P2X(7) antagonists with analgesic activity in a rat model of neuropathic pain.

Ying Wang, Prisca Honore, Qi Shuai, 2009, Journal of medicinal chemistry.

Losartan improves renal function and pathology in obese ZSF-1 rats

D. Donnelly-roberts, M. Gopalakrishnan, S. McGaraughty, 2018, Journal of basic and clinical physiology and pharmacology.

Cholinergic channel activators: novel opportunities for the treatment of CNS disorders.

D. Donnelly-roberts, S. Arneric, J. Sullivan, 1995, Proceedings of the Western Pharmacology Society.